Despite the relatively low incidence of BRAF V600E mutations in high grade gliomas, mounting evidence has suggested that BRAF targeted therapy represents a promising treatment option for adults with BRAF mutated high grade gliomas or GBM. This evidence concerns the gene BRAF and central nervous system cancer.